UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION~~

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of ~~The~~the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May 15~~June 27, 2018

SteadyMed Ltd.

(Exact name of registrant as specified in its charter)

Israel		001-36889		Not applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

5 Oppenheimer Street
Rehovot 7670105, Israel
(Address of principal executive offices, including zip code)

925-272-4999
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

ox Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 28.~~02.~~01 ~~Results~~Other ~~of Operations and Financial Condition.~~Events

On ~~May~~June 1527, 2018, ~~SteadyMed~~Richard ~~Ltd~~Scarantino ~~issued~~and aAustralia ~~press~~A. ~~release~~Hoover ~~announcing~~filed ~~its~~separate ~~financial~~putative ~~results~~class action lawsuits in the United States District Court for the ~~quarter~~Northern ~~ended~~District ~~March 31~~of California, ~~2018~~each purportedly on behalf of the stockholders of SteadyMed Ltd., Aagainst ~~copy~~SteadyMed and its directors, alleging, among other things, violations of ~~this~~sections ~~press~~14(a) and ~~release~~20(a) of isthe ~~attached~~Securities ~~hereto~~Exchange Act of 1934, as ~~Exhibit~~amended, and Rule 9914a-9 thereunder.1 The complaints each seek, among other things, to enjoin the defendants from completing the previously announced proposed merger transaction by which Daniel 24043 Acquisition Corp. Ltd. will merge with and into SteadyMed, making SteadyMed a wholly-owned subsidiary of United Therapeutics Corporation.

~~The~~SteadyMed ~~information~~and inits ~~this~~directors ~~Current~~believe ~~Report~~that ~~on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of~~ the ~~Securities~~suits ~~Exchange~~lack ~~Act~~merit ofand ~~1934,~~intend ~~as amended (the “Exchange Act”), or otherwise subject~~ to ~~the~~take ~~liability~~all ofappropriate ~~that~~actions section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to ~~this~~defend ~~Current~~against ~~Report on Form 8-K~~them.

~~Item~~It 9is possible that additional similar complaints may be filed in the future.01 ~~Financial~~If ~~Statements~~this ~~and~~does ~~Exhibits~~occur, SteadyMed does not intend to announce the filing of any similar complaints.

~~(d) Exhibits~~2

Exhibit Number		Exhibit Description
99.1		Press Release, dated May 15, 2018

SIGNATURES

2Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGNATURES

	STEADYMED LTD.

	By:	/s/ David W. Nassif
Date: June 29, 2018		David W. Nassif
		Executive Vice President and Chief Financial Officer

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~3

	STEADYMED LTD.
	By:	/s/ David Nassif
Date: May 15, 2018		David W. Nassif
		Chief Financial Officer

Filing Compare · SteadyMed Ltd.